Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

AMRI Announces Senior Level Leadership Appointment

Published: Thursday, October 17, 2013
Last Updated: Thursday, October 17, 2013
Bookmark and Share
The appointment of Michael A. Luther, Ph.D. as Senior Vice President of Discovery sees AMRI expanding its biology capabilities.

AMRI announce the appointment of Michael A. Luther, Ph.D., as Senior Vice President, Discovery, effective October 28, 2013. Dr. Luther will report to Thomas E. D’Ambra, Ph.D., President and CEO. 

Dr. Luther will lead AMRI’s global discovery organization, which provides biology and chemistry services to the biopharmaceutical industry, with locations in the U.S., Singapore and Hyderabad, India. Dr. Luther will also oversee AMRI’s expansion into Western New York via the development of the Buffalo Medical Innovation and Commercialization Hub at Buffalo Niagara Medical Campus (BNMC Hub), a new pharmaceutical research, development and testing initiative in Buffalo, N.Y. announced by New York Governor Andrew M. Cuomo in December 2012. 

Dr. Luther was most recently Corporate Vice President of Global Discovery Research Services at Charles River Laboratories, from August 2012 through September 2013, where he served as the general manager of the firm’s discovery business unit, including developing and implementing strategic and operating plans. Prior to his role at Charles River, from March 2009 through August 2012, he was President and a member of the Board of Directors of the David H. Murdock Research Institute in Kannapolis, North Carolina where he led and directed all activities of the institute, which included applied R&D activities that facilitate and accelerate discovery to proof of principle and early product development in areas of human health. Prior to this, from November 2006 through March 2009 he held the position of Vice President and Site Head at Merck Frosst at their Montreal, Canada site, focused on the delivery of Phase I candidates from target to clinic for novel therapeutics in respiratory and metabolic disorders. Prior to this, from 1991 through 2006 he held positions of increasing responsibility at GlaxoSmithKline, culminating in his appointment as Vice President, High Throughput Biology. 

“We are pleased and excited Dr. Luther is joining AMRI’s leadership team as we continue to execute our growth strategy and move forward providing high quality services to the pharmaceutical and biotechnology industries,” said Dr. D’Ambra. “Mike’s strong biology background and accomplishment, as well as his experience in both large pharma and the CRO world bring to his role the experience and network to strengthen AMRI’s position as a leading discovery partner to the industry. I am confident that Dr. Luther is the right person to lead AMRI’s strong global discovery brand to the next level as we expand the breadth and depth of our biology capabilities in line with movement by our customers seeking greater and more integrated offerings by service providers. In addition, he is joining AMRI at an exciting time as we expand in partnership with CNSE under Governor Cuomo’s leadership.”

Dr. Luther earned his Ph.D. in biophysical chemistry from St. Louis University School of Medicine; an M.B.A. from Duke University, Fuqua School of Business; and a B.Sc. in biology and chemistry from North Carolina State University. Dr. Luther has authored numerous scientific papers and serves on several Boards of Directors for both academic and industry trade organizations, including the Center for Tropical and Emerging Global Diseases and the College of Life Sciences Research Foundation, North Carolina State University. 

Dr. Luther succeeds Bruce J. Sargent, Ph.D., Senior Vice President of Drug Discovery, who has elected to retire at the end of the year. “We thank, and are grateful to, Dr. Sargent for his long and successful career at AMRI,” said Dr. D’Ambra. “Bruce joined AMRI as a Director of Medicinal Chemistry in 2001 and rose through the company to eventually become our Senior Vice President of Drug Discovery. Under Bruce’s leadership, several of our internal R&D programs achieved successful milestones, some of which have been successfully out-licensed to other parties.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Wednesday, December 16, 2015
AMRI, PerkinElmer to Collaborate on Drug Discovery
Albany Molecular Research (AMRI) and PerkinElmer are collaborating to provide drug discovery infrastructure and services in AMRI's newly launched drug discovery center.
Thursday, June 18, 2015
AMRI to Close Holywell, U.K. API Manufacturing Facility
Company plans to cease operations at the site by the end of 2015.
Thursday, April 09, 2015
AMRI Proposes To Close UK-Based API Manufacturing Facility
The proposed closure would affect approximately 64 positions.
Friday, February 20, 2015
AMRI Announces CFO Transition
Michael M. Nolan, senior vice president and chief financial officer, will be departing AMRI.
Thursday, January 15, 2015
AMRI To Acquire Aptuit Drug Product Development Businesses
Significantly expands AMRI's analytical services capabilities and extends drug product development services to include sterile injectable formulation development.
Friday, January 09, 2015
AMRI to Acquire Oso Biopharmaceuticals Manufacturing
Acquisition significantly expands contract manufacturing capabilities to include commercial scale sterile injectables.
Tuesday, June 03, 2014
AMRI to Acquire Cedarburg Pharmaceuticals, Inc.
Broadens contract development and manufacturing capabilities with high value, complex API business.
Friday, March 28, 2014
AMRI Awarded Contract from the UK Government
Seven-year contract awarded for the development and manufacture of an active ingredient under clinical evaluation.
Thursday, October 03, 2013
FDA Performs Re-inspection of AMRI Burlington MA Facility
Issues Form 483 for three inspectional observations.
Friday, July 26, 2013
AMRI Burlington Receives DEA Approval to Handle Controlled Substances
Approval to handle Schedule 2 and 2N controlled substances at this location further supports AMRI SMARTSOURCING™ offering.
Wednesday, June 19, 2013
AMRI Promotes Susan Collins to Director, Business Development
Ms. Collins is responsible for leading AMRI’s North American Discovery Business Development team.
Tuesday, June 18, 2013
AMRI Announces Appointment of Chairman of the Board of Directors
Company has appointed William S. Marth as Chairman of the Board, effective June 5, 2013.
Friday, June 07, 2013
AMRI and Ono Broaden SMARTSOURCING™ Collaboration
New agreement extends drug discovery and development collaboration between the companies.
Friday, April 26, 2013
AMRI Announces the Promotion of Richard Saffee
Company promotes Mr. Saffee to Vice President and General Manager of large scale manufacturing.
Wednesday, January 09, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Rates of Nonmedical Prescription Opioid Use Disorder Double in 10 Years
Researchers at NIH have found that the nonmedical use of prescription opioids has more than doubled among adults in the United States from 2001-2002 to 2012-2013.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!